Jazz Pharmaceuticals

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: Xyrem, Xywav, Sunosi, Erwinaze, Vyxeos, Defitelio, and Zepzelca. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Jazz Pharmaceuticals achieves record revenue in Q4 2022

Jazz Pharmaceuticals delivered strong financial performance in Q4 2022, driven by key products and a focus on operational efficiency.
The company's pipeline expansion, strategic focus, and differentiated products position it well for future growth.
While facing challenges in sales guidance and market education, Jazz Pharmaceuticals has opportunities for growth through new molecules and market expansion.
Overall, Jazz Pharmaceuticals remains optimistic about its growth trajectory, supported by product differentiation and strategic initiatives.

Jazz Pharmaceuticals excels in Q1 2023, eyes growth opportunities

Jazz Pharmaceuticals demonstrated strong financial performance and operational excellence in Q1 2023, driven by key products like Xywav and Epidiolex.
While facing challenges in patient adoption and prescriber education, the company remains focused on strategic investments and sustainable growth initiatives.
With a robust pipeline, revenue growth opportunities, and a commitment to patient impact, Jazz Pharmaceuticals is well-positioned to achieve its Vision 2025 goals.

Jazz Pharmaceuticals excels in Q2, eyes pipeline growth opportunities

Jazz Pharmaceuticals demonstrated strong commercial performance and financial growth in Q2 2023, driven by key product successes and pipeline advancements.
While facing operational challenges, the company's strategic strengths in capital allocation, R&D focus, and market positioning bode well for future growth.
With a clear focus on Vision 2025 targets, Jazz Pharmaceuticals remains confident in its ability to navigate challenges and capitalize on growth opportunities.

Jazz Pharmaceuticals reports strong Q3 performance and eyes global expansion

Jazz Pharmaceuticals' Q3 earnings call reflects robust sales growth, strategic initiatives to drive key products towards blockbuster status, and a focus on innovation in therapeutic treatments.
The company's strengths in revenue diversification, global expansion plans for Epidiolex, and confidence in upcoming treatments position it well for sustained growth in the pharmaceutical market.
While facing challenges in market competition and revenue dynamics, Jazz Pharmaceuticals is poised to capitalize on opportunities in global market expansion, new oncology assets, and innovative treatment approaches.

Jazz Pharmaceuticals excels in Q4, eyes growth through innovation

Jazz Pharmaceuticals delivered strong financial results, driven by key products like Xywav, Epidiolex, and Rylaze, showcasing revenue growth and profitability.
The company's focus on oncology and neuroscience, with late-stage catalysts and global expansion plans, highlights a commitment to innovation and market leadership.
While facing challenges in a competitive landscape, Jazz Pharmaceuticals remains poised for growth through strategic initiatives, R&D advancements, and product differentiation.
Overall, Jazz Pharmaceuticals' performance, strengths, and opportunities position it well for sustained growth and value creation in the pharmaceutical industry.

Jazz Pharma excels in Q1 2024, eyes growth in oncology and neuroscience

Jazz Pharmaceuticals delivered strong Q1 2024 results, driven by revenue growth and key product performance in oncology and neuroscience.
The company's disciplined capital allocation and strategic investments position it well for future growth and innovation in its pipeline.
While facing challenges in clinical trials and competitive markets, Jazz Pharma remains focused on leveraging strengths and seizing growth opportunities.

Jazz Pharmaceuticals achieves record revenues, updates guidance for 2024

Jazz Pharmaceuticals delivered exceptional financial performance in Q2 2024 with record revenues.
Key products showed strong sales growth, reflecting market acceptance and demand.
The company's focus on long-term value creation through investments and guidance update is notable.
Challenges include maintaining growth momentum and successful data readouts from late-stage programs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Jazz Pharmaceuticals Plc operates as a biopharmaceutical company, which focuses on the identification, development, and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain, and psychiatry. Its product portfolio includes: Xyrem, Xywav, Epidolex, Zepzelca, Rylaze, Vyxeos, and Defitelio. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.

Progress of its pipeline candidates and launch of Sunosi is likely to have increased Jazz Pharmaceuticals (JAZZ) operating expenses in the fourth quarter. Xyrem likely to have continued strong demand trend.

What Awaits Jazz Pharmaceuticals (JAZZ) in Q4 Earnings?

On Tuesday, Jazz Pharmaceuticals got an upgrade for its IBD SmartSelect Composite Rating from 94 to 96. 
The post Highly Rated Jazz Pharmaceuticals Sees A Hike In Its Composite Rating appeared first on Investor's Business Daily.

Highly Rated Jazz Pharmaceuticals Sees A Hike In Its Composite Rating

Elevate Credit

Exxon Mobil

By historical standards, all three of these businesses are now bargains.

3 Top Value Stocks You'll Want to Own in February

Jazz (JAZZ) files regulatory application seeking approval for JZP-258, a low sodium formulation of Xyrem, in the United States.

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised)

Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258

The company's submitted an application for approval of JZP-258, a treatment for cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy.

Jazz Pharma Files for FDA Approval of a New Narcolepsy Drug

Jazz (JAZZ) receives approval for Sunosi as a treatment for excessive daytime sleepiness in narcolepsy or obstructive sleep apnea patients in Europe.

Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe

Farfetch

You might want to add a luxury e-tailer and a sleep-disorder specialist to your buy list.

2 Stocks That Are Absurdly Cheap Right Now: FTCH & JAZZ

The IBD SmartSelect Composite Rating for Jazz Pharmaceuticals increased from 94 to 96 Monday. 
The post Jazz Pharmaceuticals Sees Composite Rating Improve To 96 appeared first on Investor's Business Daily.

Jazz Pharmaceuticals Sees Composite Rating Improve To 96

ABIOMED

ACADIA Pharma

Accelerate Diagnostics

DexCom

Exact Sciences

Neurocrine Biosciences

NeoGenomics

Repligen

Simulations Plus

The 10 Best Healthcare Stocks of the Decade

Jazz (JAZZ) begins enrollment in the phase II/III study evaluating JZP-458 for treating pediatric and adult patients with acute lymphoblastic leukemia, hypersensitive to E. coli-derived asparaginases

Jazz Enrolls First Patient in Phase II/III Leukemia Study

Align Technology

Amedisys

LHC Group

Mastercard

Moody's

Veeva Systems

The prospects of growth stocks appear bright for 2020, making the following companies attractive bets.

7 Impressive Growth Stocks to Buy for 2020

Barclays

Lithia Motors

Marathon Petroleum

Meritage Homes

If you are not sure whether to invest your money in bonds or stocks, a key parameter that can show you the right direction is earnings yield.

5 High Earnings Yield Stocks for a Standout Portfolio

Is  (JAZZ) Outperforming Other Medical Stocks This Year?

Is Jazz Pharmaceuticals (JAZZ) Outperforming Other Medical Stocks This Year?

Jazz (JAZZ) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Jazz (JAZZ) Hits 52-Week High, Can the Run Continue?

Alexion Pharma

Changyou.com Ltd.

Legg Mason

Navient

Quanta Services

P/B ratio is emerging as a convenient tool for identifying low-priced stocks with high-growth prospects.

5 Low Price-to-Book Value Stocks to Buy as 2020 Nears

Here is why Jazz Pharmaceuticals could survive the threat from generics for its top-selling product.

Up 25% in 2 Months, This Healthcare Stock Could Climb Even Higher

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Should Value Investors Buy Jazz Pharmaceuticals (JAZZ) Stock?

6 Low Price-to-Book Value Stocks to Buy in December

Jazz Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 79 to 83.

Stocks To Watch: Jazz Pharmaceuticals Sees Relative Strength Rating Jump To 83

Broadcom

Domino's Pizza

MarketAxess Holdings

Netflix

United Rentals

These ten growth stocks saw the highest percentage growth over the last decade, and some remain unknown to investors despite huge increases.

10 Best-Performing Growth Stocks of the 2010s

Jazz (JAZZ) reported earnings 30 days ago. What's next for the stock?

Jazz (JAZZ) Up 16.4% Since Last Earnings Report: Can It Continue?

AXA Equitable Holdings Inc

Seaspan

Tenet Healthcare

Although PEG is categorized under value investing, it follows the principles of both growth and value investing.

5 Discounted PEG Stocks for GARP Investors

Shares of IBD 50 stock Jazz Pharmaceuticals dipped Tuesday after Axsome Therapeutics unveiled promising Phase 2 test results for a rival narcolepsy treatment, known by the test name AXS-12.
The post How A Rival Narcolepsy Drug Sent This IBD 50 Stock Tumbling appeared first on Investor's Business Daily.

How A Rival Narcolepsy Drug Sent This IBD 50 Stock Tumbling

Jazz (JAZZ) possesses solid growth attributes, which could help it handily outperform the market.

3 Reasons Growth Investors Will Love Jazz (JAZZ)

News for Jazz Pharmaceuticals Stock (JAZZ)